FDA Widens Approval for Advanced Spinal Fusion Bone Graft

WESTMINSTER, CO – January 13, 2026 – By Sharon Kelly – Patients suffering from debilitating degenerative disc disease now have broader access to a novel treatment proven to accelerate spinal healing. The U.S. Food and Drug Administration (FDA) today announced it has granted expanded approval for Cerapedics Inc.'s PearlMatrix P-15 Peptide Enhanced Bone Graft, a first-of-its-kind therapy for lumbar spinal fusion.

This landmark decision significantly widens the clinical applications for PearlMatrix, making it the only Class III drug-device spinal bone graft approved for all major lumbar interbody fusion surgical approaches. The expanded labeling now includes anterior, posterior, oblique, and lateral surgical techniques, in addition to its original approval for transforaminal lumbar interbody fusion. This versatility gives surgeons unprecedented flexibility to choose the optimal procedure for each patient's unique anatomy and condition, potentially improving outcomes for a larger patient population.

A Breakthrough for Surgical Flexibility

The expanded indication is a pivotal development in a market where lumbar fusion procedures account for roughly two-thirds of all spinal fusions. Previously, PearlMatrix was approved for use only in transforaminal lumbar interbody fusion (TLIF) procedures and with specific PEEK polymer cages. The new approval extends its use to anterior (ALIF), posterior (PLIF), oblique (OLIF), and lateral (LLIF) approaches, whether performed as open or minimally invasive surgery.

Furthermore, the graft can now be used with a wider array of interbody fusion cages, including those made from titanium alloy and PEEK/titanium combinations. This allows surgeons to pair the advanced biologic with their preferred implant hardware, streamlining its integration into established surgical workflows.

The strategic path to this broad approval was intentional, according to the company. "The label expansion for PearlMatrix reflects the strength of our clinical evidence," noted Valeska Schroeder, PhD, Chief Executive Officer of Cerapedics. "We strategically selected the TLIF approach for our ASPIRE study due to the complexity of the procedure to create a high bar of evidence before submitting our supplemental application to expand to other lumbar surgical approaches. Now, even more patients have the opportunity to benefit from accelerated lumbar fusion with PearlMatrix."

The Science of Accelerated Bone Growth

At the heart of PearlMatrix is a unique biomimetic technology. The product is a drug-device combination that utilizes a proprietary 15 amino-acid sequence known as P-15 Peptide. This peptide is a synthetic fragment of Type-1 collagen, the primary protein that forms the structural matrix of natural bone.

In a fusion procedure, the P-15 Peptide acts as a powerful cell attachment factor. Bound to a scaffold of calcium phosphate particles, it creates an environment rich with attachment sites for the patient's own osteogenic (bone-forming) cells. This attachment triggers a cascade of natural cellular processes, signaling the cells to activate and begin forming new, healthy bone at an accelerated rate.

This mechanism distinguishes PearlMatrix from other bone graft options. Traditional autograft, long considered the gold standard, requires harvesting bone from another part of the patient's body (typically the hip), which involves a second surgical site and the risk of chronic pain and other complications. Allografts, which use donor bone, carry a small risk of disease transmission and may have less predictable fusion rates. Synthetic grafts, while avoiding these issues, often lack the potent biological signaling needed for rapid, robust fusion. PearlMatrix aims to provide the biological advantages of an autograft without the need for a secondary harvest site.

Backed by Rigorous Clinical Evidence

The FDA’s decision was underpinned by robust clinical data, primarily from the ASPIRE pivotal study, which led to PearlMatrix's initial premarket approval (PMA) in June 2025. The prospective, single-blinded, multicenter, randomized, and controlled study is considered a high standard for clinical evidence in the medical device field.

The results, now published in the peer-reviewed journal Spine, compared PearlMatrix to the use of a local autograft in TLIF surgery. The study demonstrated that PearlMatrix was statistically superior in Composite Clinical Success, a comprehensive endpoint measuring fusion, neurological status, and pain/function improvement. Crucially, it also showed a statistically superior speed of fusion, meaning patients achieved a solid fusion faster than those treated with autograft, with a comparable safety profile.

The strength of this evidence is a key differentiator in a crowded market. "The expanded on-label indications for PearlMatrix, now including all major lumbar interbody fusion procedures, will give many more patients the opportunity to benefit from its proven efficacy," said Dr. Isaac L. Moss, Professor and Chair of Orthopedic Surgery at the University of Connecticut. "The ASPIRE trial provides some of the most rigorous scientific evidence we have for any bone graft substitute on the market, as it demonstrated safety and improved time-to-fusion in both the overall and high risk-patient populations (i.e., patients with Type 2 diabetes, BMI ≥ 30 and/or nicotine users)."

The inclusion of high-risk patients, who are notoriously difficult to treat and often have slower healing, adds significant weight to the findings and suggests a broad clinical utility for the product.

Reshaping the Spinal Fusion Market

This expanded approval positions Cerapedics to make a significant impact on the lucrative and expanding spinal fusion market. The global lumbar spine fusion market was valued at over $8.4 billion in 2023 and is projected to grow at a CAGR of 6.4% through 2032, driven by an aging population and the rising prevalence of degenerative spinal conditions.

The market has long been dominated by orthopedic giants like Medtronic, Johnson & Johnson, and Stryker. However, Cerapedics is carving out a powerful niche with its focus on advanced biologics backed by Class III drug-device level evidence. This high regulatory classification requires a level of scientific and clinical rigor far beyond that of most other bone graft substitutes, which are typically cleared as less-stringent Class II devices.

The trend toward minimally invasive surgery (MIS) also plays to PearlMatrix's strengths. MIS approaches are designed to reduce tissue trauma and shorten recovery times, and the availability of an advanced biologic that accelerates fusion complements these goals perfectly. By offering a single, versatile product that can be used across the full spectrum of modern lumbar fusion techniques, Cerapedics is poised to capture the attention of surgeons who value both innovation and flexibility. This approval is not just a win for the company, but a significant step forward in the evolution of spinal care, offering a more predictable and accelerated path to recovery for patients plagued by chronic back pain.